Why Are Phio Pharmaceuticals Shares Trading Higher Today

Phio Pharmaceuticals Corp PHIO shares are gaining after the FDA cleared its Investigational New Drug (IND) application to proceed with a clinical trial of Phio's lead product candidate, PH-762

PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. 

Phio plans to initiate its Phase 1b clinical trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell in the second half of 2023.

Also Read: Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients.

The initial multi-center, dose-escalating, Phase 1b trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762.

Phio will focus its efforts on the U.S. trial and intends to wind down its first-in-human clinical trial for PH-762 in France, which was limited to treating patients with metastatic melanoma.

PH-762 has also received clearance to proceed under an IND sponsored by AgonOx Inc in a clinical trial evaluating PH-762 treated "double positive" (DP) CD8 tumor-infiltrating lymphocytes (TIL) in patients with melanoma and other advanced solid tumors.

Price Action: PHIO shares are up 30% at $4.38 on the last check Tuesday.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!